Improved FcγRIIb targeting functionally translates into enhanced inhibition of basophil activation

International Archives of Allergy and Immunology

Volumn 163, Issue 3, 2014, Pages 206-214

  Buschor, Patrick ^a   Eggel, Alexander ^a   Zellweger, Fabian ^a   Stadler, Beda M ^a   Vogel, Monique ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Allergy treatment; Basophil inhibition; Fc RIIb affinity; IgE

Indexed keywords

ANTIALLERGIC AGENT; DE53 FC FUSION PROTEIN; DNA; FC RECEPTOR IIB; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 13; LEUKOTRIENE C4; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC REACTION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BASOPHIL; BASOPHIL DEGRANULATION; BINDING AFFINITY; CELL ACTIVATION; CHO CELL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; LIGAND BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN TARGETING; RECEPTOR AFFINITY; SITE DIRECTED MUTAGENESIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KINETICS; LEUKOCYTE ACTIVATION; PROTEIN BINDING; SUPERNATANT;

ANTIBODY AFFINITY; BASOPHILS; CELL DEGRANULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN E; RECEPTORS, IGE; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 84895705286     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000358487     Document Type: Article

References (27)

1. Gibbs BF, Haas H, Falcone FH, Albrecht C, Vollrath IB, Noll T, et al: Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur J Immunol 1996; 26: 2493-2498.
2. Geha R, Jabara H, Brodeur S: The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003; 3: 721-732.
3. van Beek AA, Knol EF, de Vos P, Smelt MJ, Savelkoul H, van Neerven R: Recent developments in basophil research: do basophils initiate and perpetuate type 2 T-helper cell responses? Int Arch Allergy Immunol 2012; 160: 7-17.
4. Torigoe C, Metzger H, Inman: An Unusual Mechanism for Ligand Antagonism. Science 1998 Jul 24; 281: 568-572.
5. Cassard L, Jönsson F, Arnaud S, Daëron M: Fcγ Receptors Inhibit Mouse and Human Basophil Activation. J Immunol 2012; 189: 2995-3006.
6. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV: A 13-aminoacid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling 1994; 369: 340.
7. Ono M, Bolland S, Tempst P, Ravetch JV: Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 1996; 383: 263-266.
8. Nimmerjahn F, Ravetch JV: Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
9. Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995 Feb;95: 577-585.
10. Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, et al: Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. J Allergy Clin Immunol 2000; 106: 337-348.
11. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A: A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11: 446-449.
12. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al: Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285: 20850-20859.
13. Tam SW, Demissie S, Thomas D, Daëron M: A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59: 772-780.
14. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A: A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8: 518-521.
15. Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M: Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 2011; 66: 961-968.
16. Handlogten MW, Kiziltepe T, Serezani AP, Kaplan MH, Bilgicer B: Inhibition of weakaffinity epitope-IgE interactions prevents mast cell degranulation. Nat Chem Biol 2013; 9: 789-795.
17. Baumann MJ, Eggel A, Amstutz P, Stadler BM, Vogel M: DARPins against a functional IgE epitope. Immunol Lett 2010; 133: 78-84.
18. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-59.
19. Tschopp CM: Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma. Blood 2006; 108: 2290-2299.
20. Zurcher A, Derer T, Lang A, Stadler B: Culture and IgE synthesis of nasal B cells. Int Arch Allergy Immunol 1996; 111: 77-82.
21. 1variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591-6604.
22. Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D: Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clinical Immunol 1991; 88: 328-338.
23. Allen LC, Kepley CL, Saxon A, Zhang K: Modifications to an Fcgamma-Fcepsilon fusion protein alter its effectiveness in the inhibition of FcepsilonRI-mediated functions. J Allergy Clin Immunol 2007; 120: 462-468.
24. Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE: Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb. Immunol Lett 2012; 143: 34-43.
25. Van Scott MR, Mertsching E, Negrou E, Miles J, Stallings HW, Graff C, et al: Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates. Clin Immunol 2008; 128: 340-348.
26. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 2008; 45: 3926-3933.
27. Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN: Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J Mol Biol 2012; 420: 1-7.